AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Oct 2021: Trial started, NCT05123482
  2. 17 Nov 2021: Trial registered, NCT05123482

The trials

NCT05123482: A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
460 planned
Started
18 Oct 2021
Primary completion
29 Sep 2027
Arms
Sub-Study 4: AZD8205 in combination with AZD9574 with or without rilvegostomig (AZD2936)
Results
None posted
  1. 18 Oct 2021: Trial started
  2. 17 Nov 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.